Are the DOAC plasma level thresholds appropriate for clinical decision-making? A reappraisal using thrombin generation testing

Int J Lab Hematol. 2021 Feb;43(1):e48-e51. doi: 10.1111/ijlh.13356. Epub 2020 Oct 10.

Jonathan Evrard¹, Michaël Hardy^{2

3}, Jean-Michel Dogné^{1

4}, Sarah Lessire², Vincent Maloteau¹, François Mullier³, Jonathan Douxfils^{1

5}

¹ Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.
² Department of Anesthesiology, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université catholique de Louvain, Yvoir, Belgium.
³ Hematology Laboratory, CHU UCL Namur, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université catholique de Louvain, Yvoir, Belgium.
⁴ Namur Biobank-eXchange (NAB-X), University of Namur, Namur, Belgium.
⁵ Qualiblood s.a, Namur, Belgium.

No abstract available

Keywords: dabigatran; direct oral anticoagulants; factor Xa inhibitors; thrombin generation; thrombolysis thresholds.

Publication types